A recent FDA workshop brought new diabetes outcome measures to the table, focusing on patient-oriented end points.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Use of wearable biometric monitoring devices to measure outcomes in randomized clinical trials: a methodological systematic review
BMC Medicine Open Access 06 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Kingwell, K. FDA eyes new diabetes end points. Nat Rev Drug Discov 15, 666–667 (2016). https://doi.org/10.1038/nrd.2016.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.202
This article is cited by
-
Use of wearable biometric monitoring devices to measure outcomes in randomized clinical trials: a methodological systematic review
BMC Medicine (2020)
-
Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
Nature Reviews Drug Discovery (2017)